Soluble TREM2 (sTREM2) is a protein that is shed from the surface of microglia, the immune cells of the brain and spinal cord. sTREM2 can be detected in the cerebrospinal fluid (CSF) and plasma, its levels are elevated in a variety of neurological disorders, including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis.


sTREM2 in Neuropathology

sTREM2 is a potential biomarker for microglial activation and neuroinflammation. Studies have shown that CSF sTREM2 levels are elevated in early stages of Alzheimer’s disease, even before the onset of cognitive symptoms. sTREM2 levels are also elevated in other neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

In addition to its role as a biomarker, sTREM2 may also play a direct role in the pathogenesis of neurodegenerative diseases. Studies have shown that TREM2 deficiency leads to impaired microglial function and increased neuroinflammation. TREM2 also plays a role in the clearance of amyloid-beta and tau proteins, which are two of the key pathological hallmarks of Alzheimer’s disease.

Applications and Intended Use

The sTREM2 Advantage PLUS assay is an immunoassay intended for the measurement of Soluble Triggering Receptor Expressed on Myeloid cells 2 (sTREM2) in human CSF and plasma samples.

Compatible Instruments

  • Advantage Plus: HD-X

Kit Contents

The assay kit includes all necessary reagents and controls to perform 96 tests, making it easy to use and compatible with various sample types.

Related Resources